Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer

Cancer

Volumn 109, Issue 10, 2007, Pages 1933-1939

  Lipton, Allan ^a   Ali, Suhail M ^a,b   Leitzel, Kim ^a   Demers, Laurence ^a   Evans, Dean B ^c   Hamer, Peter ^d   Brown Shimer, Sheryl ^d   Pierce, Karen ^d   Carney, Walter ^d  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Oncogene Science Biomarker Group   (United States)

Author keywords

Biomarker; Breast cancer; Clinical benefit rate; Enzyme linked immunosorbent assay; Hormone receptor status; Matrix metalloproteinases; Overall survival; Predictive and prognostic factor; Time to progression; TIMP 1

Indexed keywords

EDETIC ACID; FADROZOLE; GROWTH FACTOR; MATRIX METALLOPROTEINASE; MEGESTROL ACETATE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; UNIVARIATE ANALYSIS; VISCERAL METASTASIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FADROZOLE; FEMALE; HUMANS; MEGESTROL ACETATE; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL RATE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL;

EID: 34248331636     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22637     Document Type: Article

References (31)

1. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997;89:1260-1270.
2. Remacle AG, Noel A, Duggan C, et al. Assay of matrix metalloproteinases types 1,2,3, and 9 in breast cancer. Br J Cancer. 1998;77:926-931.
3. Rha SY, Yang WI, Kim JH, et al. Different expression patterns of MMP-2 and MMP-9 in breast cancer. Oncol Rep. 1998;5:875-879.
4. Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteases and their inhibitors in tumor invasion, metastasis and angiogenesis. Eur Respir J. 1994;7:2062-2072.
5. Apte SS, Olsen BR, Murphy G. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Bio Chem. 1995;270:14313-14318.
6. Goldberg GI, Strongin A, Collier IE, et al. Interaction of 92-kDa Type IV collagenase with the tissue inhibitor of metallproteinases prevents dimerization, complex formation with interstitial collagenase and activation of the proenzyme with stromelysin. J Biol Chem. 1992;267:4583-4591.
7. Cox G, Steward WP, O'Bryne KJ. The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. Thorax. 1999;54:169-179.
8. Brew K, Dinakarpandian D, Nagase N. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000;1477:267-283.
9. Bertaux B, Hornebeck W, Eisen AZ, et al. Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J Invest Dermatol. 1991;97:679-685.
10. Hayakawa T, Yamashita K, Tanzawa K, et al. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett. 1992;298:29-32.
11. Alexander CM, Howard EW, Bissell MJ, Werb Z. Rescue of mammary epithelial apoptosis and entactin degradation by a tissue inhibitor of metalloproteinase-1 transgene. J Cell Biol. 1996;135:1669-1677.
12. Li G, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res. 1999;59:6267-6275.
13. Guedez L, Stetler-Stevenson WG, Wolff L, et al. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Investig. 1998;102:2002-2010.
14. Gasson JC, Golde DW, Kaufman SE, et al. Molecular characterization and expression of the gene encoding human erythroid-potentiating activity. Nature (London). 1985;315:768-771.
15. Yoshiji J, Harris SR, Raso E, et al. Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int J Cancer. 1998;75:81-87.
16. Laleur MA, Handsley MM, Knauper V, Murphy G, Edwards DR. Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metallproteinases (MT-MMPs). J Cell Sci. 2002;115:3427-3428.
17. Fernandez HA, Kallenback K, Seghezzi G, et al. Inhibition of endothelial cell migration by gene transfer of tissue inhibitor of metalloproteinases-1. J Surg Res. 1999;82:156-162.
18. Zeng ZS, Cohen AM, Zhang ZF, et al. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res. 1995;1:899-906.
19. Mimori K, Mori M, Shiraishi T, et al. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer. 1997;76:531-536.
20. Karavasilis V, Malamou-Mitsi V, Briasoulis E, et al. Matrix metalloproteinases in carcinoma of unknown primary. Cancer. 2005;104:2282-2287.
21. Ree AH, Florenes VA, Berg JP, et al. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res. 1997;3:1623-1628.
22. Guedez L, McMarlin AJ, Kingma DW, Bennett TA, Stetler-Stevenson M, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects of tumor growth and angiogenesis. Am J Pathol. 2001;158:1207-1215.
23. Gouyer V, Conti M, Devos P, et al. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent. Cancer. 2005;103:1676-1684.
24. Schrohl A-S, Holten-Andersen MN, Peters HA, et al. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res. 2004;10:2289-2298.
25. Holten-Andersen MN, Stephens RW, Nielsen HJ, et al. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res. 2000;6:4292-4299.
26. Buzdar AU, Smith R, Vogel C, et al. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma. Cancer. 1996;77:2503-2513.
27. Docherty AJ, Lyons A, Smith BJ, et al. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature. 1985;318:66-69.
28. Voorzanger-Rousselot N, Juillet F, Mareau E, Zimmermann J. Kalebic T, Garnero P. Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation. Br J Cancer. 2006;95:506-514.
29. Wurtz SO, Schrohl AS, Sorensen NM, et al. Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocrine-Related Cancer.12:215- 27, 2005.
30. Luparello C, Avanzato G, Carella C, Pucci-Minafra I. Tissue inhibitor of metalloprotease (TIMP)-1 and proliferative behaviour of clonal breast cancer cells. Breast Cancer Res Treat. 1999;54:235-244.
31. Yamashita K, Suzuki M, Iwata H, et al. Tyrosine phosphorylation is crucial for growth signaling by tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2). FEBS Lett. 1996;396:103-107.